Alzheimer disease (AD) is the most common contributor to dementia in the world, but
strategies that slow or prevent its clinical progression have largely remained elusive, until …

Alzheimer disease (AD) is the most common cause of dementia in older individuals. AD is
characterized pathologically by amyloid-β (Aβ) plaques and tau neurofibrillary tangles in the …

Tau protein is involved in various cellular processes, including having a canonical role in
binding and stabilization of microtubules in neurons. Tauopathies are neurodegenerative …

Alzheimer's disease (AD) research has entered a new era with the recent positive phase 3
clinical trials of the anti-Aβ antibodies lecanemab and donanemab. Why did it take 30 years …

Novel agents addressing non-amyloid, non-tau targets in Alzheimer's Disease (AD)
comprise 70% of the AD drug development pipeline of agents currently in clinical trials. Most …

Nucleic acid-based therapies have become the third major drug class after small molecules
and antibodies. The role of nucleic acid-based therapies has been strengthened by recent …

Neuronal loss is the central issue in Alzheimer's disease (AD), yet no treatment developed
so far can halt AD-associated neurodegeneration. Here, we developed a monoclonal …

Alzheimer's disease (AD) is the most common neurodegenerative disease characterized by
cognitive impairment with few therapeutic options. Despite many failures in develo** AD …

Importance Accumulation of hyperphosphorylated, tangled microtubule-associated protein
tau (MAPT) is a pathological hallmark of Alzheimer disease (AD) associated with disease …

Abstract p75 neurotrophin receptor (p75NTR) signaling pathways substantially overlap with
degenerative networks active in Alzheimer disease (AD). Modulation of p75NTR with the first …